Radient Pharmaceuticals Ships Onko-Sure® Test Kits to Brazil and Files Patent in Brazil

Radient Pharmaceuticals Corporation, has announced that it has sold and shipped its first order of Onko-Sure® test kits to a distributor in Brazil.

This initial shipment of kits will be used by the in-country distributor for regulatory approval and clinical validation of the test in Brazilian labs.

Prior to the shipment of these test kits, Radient filed for patent protection for Onko-Sure® in Brazil.

The Onko-Sure® test kit is a 96-well ELISA test kit sold to clinical reference labs. Labs run individual tests prescribed by doctors. Forty tests can be run, in duplicate, on each test kit.

Onko-Sure® is a non-invasive cancer blood test that has been shown, in a large body of published clinical research, to be effective in the detection of 19 different cancers.

According to Kalorama Information, Brazil spent $126 billion on healthcare in 2009. Brazil's in vitro diagnostic market has nearly doubled since 2003 and is growing at a rate that is faster than the average rate of growth for the IVD market worldwide.

With a population of approximately 190 million, Brazil is by far the most populous country in South America.

Radient Chairman and CEO, Douglas MacLellan, commented, "Brazil is key for us in both addressing the cancer challenge in one of the top global emerging healthcare markets, as well as in establishing a base for expanding Onko-Sure® use into the rest of South America."

"We are actively collaborating with our Brazilian partners for rapid regulatory progress and clinical lab adoption. Our first sale of kits is supporting these important efforts," added Chris Gee, Director of International Sales and Marketing for Radient.